Treatment initiation for parkinson's disease in Australia 2013-2018: a nation-wide study.
Antiparkinson drugs
Australia
Parkinson’s disease
Pharmacoepidemiology
Sex differences
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
03 06 2022
03 06 2022
Historique:
received:
09
12
2021
accepted:
19
04
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Guidelines highlight the importance of an individualized approach to treatment initiation for Parkinson's disease. Our aim was to investigate initiation of anti-Parkinson medication in Australia from 2013-2018, and to determine factors predicting choice of initial treatment. Cohort of new-users (N = 4,887) of anti-Parkinson medication aged ≥ 40 years were identified from a 10% random representative sample of national medication dispensing data from July-2013 to June-2018. Changes in treatment initiation were examined across the whole cohort and stratified by age and sex. Treatment initiation was most frequent with levodopa followed by non-ergot dopamine agonists (DAs) and anticholinergics. Two thirds initiated with levodopa across the study period. Initiation with non-ergot DAs increased from 22 to 27% (rate ratio, RR 1.23, 95% confidence interval, CI 1.02-1.47) and initiation with anticholinergics decreased from 6.9% to 2.4% (RR 0.34, 95% CI 0.21-0.55) from 2013-2018. Among persons aged ≥ 65 years, one third of women and one fourth of men initiated on levodopa. Among women aged < 65 years, rates of treatment initiation with DAs (37%) and levodopa (37%) were similar in 2013/2014 but initiation with DA exceeded levodopa thereafter. Among men aged < 65 years, treatment initiation with levodopa (44%-49%) remained more frequent than initiation with DAs (29%-32%) throughout the study period. Treatment initiation with levodopa was most frequent among persons aged ≥ 65 years, consistent with current guidelines. Whilst the value of levodopa sparing strategies is unclear, treatment initiation with DA has become increasingly common relative to levodopa among women but not among men aged < 65 years.
Sections du résumé
BACKGROUND
Guidelines highlight the importance of an individualized approach to treatment initiation for Parkinson's disease. Our aim was to investigate initiation of anti-Parkinson medication in Australia from 2013-2018, and to determine factors predicting choice of initial treatment.
METHODS
Cohort of new-users (N = 4,887) of anti-Parkinson medication aged ≥ 40 years were identified from a 10% random representative sample of national medication dispensing data from July-2013 to June-2018. Changes in treatment initiation were examined across the whole cohort and stratified by age and sex.
RESULTS
Treatment initiation was most frequent with levodopa followed by non-ergot dopamine agonists (DAs) and anticholinergics. Two thirds initiated with levodopa across the study period. Initiation with non-ergot DAs increased from 22 to 27% (rate ratio, RR 1.23, 95% confidence interval, CI 1.02-1.47) and initiation with anticholinergics decreased from 6.9% to 2.4% (RR 0.34, 95% CI 0.21-0.55) from 2013-2018. Among persons aged ≥ 65 years, one third of women and one fourth of men initiated on levodopa. Among women aged < 65 years, rates of treatment initiation with DAs (37%) and levodopa (37%) were similar in 2013/2014 but initiation with DA exceeded levodopa thereafter. Among men aged < 65 years, treatment initiation with levodopa (44%-49%) remained more frequent than initiation with DAs (29%-32%) throughout the study period.
CONCLUSIONS
Treatment initiation with levodopa was most frequent among persons aged ≥ 65 years, consistent with current guidelines. Whilst the value of levodopa sparing strategies is unclear, treatment initiation with DA has become increasingly common relative to levodopa among women but not among men aged < 65 years.
Identifiants
pubmed: 35658842
doi: 10.1186/s12877-022-03095-3
pii: 10.1186/s12877-022-03095-3
pmc: PMC9166304
doi:
Substances chimiques
Antiparkinson Agents
0
Cholinergic Antagonists
0
Dopamine Agonists
0
Levodopa
46627O600J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
483Informations de copyright
© 2022. The Author(s).
Références
Pharmacoepidemiol Drug Saf. 2011 May;20(5):450-6
pubmed: 21322083
BMC Res Notes. 2015 Nov 02;8:634
pubmed: 26526064
J Parkinsons Dis. 2019;9(4):749-759
pubmed: 31424419
Lancet Neurol. 2015 Jan;14(1):57-64
pubmed: 25435387
Parkinsonism Relat Disord. 2014 Jan;20(1):69-74
pubmed: 24183677
Med J Aust. 2019 Sep;211(6):277-283
pubmed: 31203580
Can J Neurol Sci. 2012 Jul;39(4 Suppl 4):S1-30
pubmed: 23126020
J Parkinsons Dis. 2019;9(3):501-515
pubmed: 31282427
Transl Neurodegener. 2016 Jun 30;5:12
pubmed: 27366321
Mov Disord. 2012 Apr;27(4):485-91
pubmed: 21953990
J Neurol. 2017 Aug;264(8):1583-1607
pubmed: 28054129
JAMA. 2014 Apr 23-30;311(16):1670-83
pubmed: 24756517
BMJ Open. 2018 Apr 13;8(4):e021122
pubmed: 29654048
Lancet. 2014 Sep 27;384(9949):1196-205
pubmed: 24928805
Mov Disord. 2018 Aug;33(8):1248-1266
pubmed: 29570866
Eur J Neurol. 2013 Jan;20(1):5-15
pubmed: 23279439
Curr Neuropharmacol. 2016;14(4):356-63
pubmed: 26644151
Br J Clin Pharmacol. 2009 Feb;67(2):228-33
pubmed: 19094158